Impact of COVID-19 on the global supply chain of antiretroviral drugs: a rapid survey of Indian manufacturers
- PMID: 32978345
- DOI: 10.4103/2224-3151.294306
Impact of COVID-19 on the global supply chain of antiretroviral drugs: a rapid survey of Indian manufacturers
Abstract
Most people living with HIV in low- and middle-income countries are treated with generic antiretroviral (ARV) drugs produced by manufacturers in India - the "pharmacy of the developing world". India's nationwide lockdown in March 2020 in response to the coronavirus disease 2019 (COVID-19) pandemic therefore prompted concerns about disruption to this essential supply. A preliminary assessment of ARV drug manufacturers in India in March 2020 indicated a range of concerns. This prompted a rapid questionnaire-based survey in May 2020 of eight manufacturers that account for most of India's ARV drug exports. The greatest challenges reported were in international shipping, including delays, increased lead times and rising costs. Contrary to expectations, lack of access to the active pharmaceutical ingredients (APIs) required for ARV drug manufacture was not a major hindrance, as manufacturers reported that their reliance on China for API supplies had reduced in recent years. However, their reliance on overseas markets for the raw materials required for local API synthesis was a major challenge. The findings from this survey have implications for addressing some of the immediate and medium-term concerns about the production and supply of generic ARV drugs. Long-term orders to support multi-month dispensing and buffer stocks need to be in place, together with computerized inventory management systems with real-time information from the lowest-level dispensation unit. Manufacturers and industry associations should have regular, formal interaction with the key ministries of the Government of India regarding these issues. Measures to improve the resilience of the generic ARV drug supply system are essential to minimize ongoing supply shocks resulting from the COVID-19 pandemic and to prepare for future emergencies.
Keywords: COVID-19; HIV; India; antiretroviral drugs; manufacturers; shortages; supply chain.
Conflict of interest statement
None declared. Furthermore, the authors declare that the responses received from the pharmaceutical companies for this assessment were provided purely on a voluntary basis and that the use of these responses in the analysis undertaken in this paper will not result in any endorsement of the pharmaceutical products produced by those companies or their preferential treatment
Similar articles
-
A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.J Int AIDS Soc. 2010 Sep 14;13:35. doi: 10.1186/1758-2652-13-35. J Int AIDS Soc. 2010. PMID: 20840741 Free PMC article.
-
[Quick community survey on the impact of COVID-19 outbreak for the healthcare of people living with HIV].Zhonghua Liu Xing Bing Xue Za Zhi. 2020 May 10;41(5):662-666. doi: 10.3760/cma.j.cn112338-20200314-00345. Zhonghua Liu Xing Bing Xue Za Zhi. 2020. PMID: 32223840 Chinese.
-
COVID-19 pandemic and antiretrovirals (ARV) availability in Nigeria: recommendations to prevent shortages.Pan Afr Med J. 2020 Aug 24;35(Suppl 2):149. doi: 10.11604/pamj.supp.2020.35.149.25639. eCollection 2020. Pan Afr Med J. 2020. PMID: 33193964 Free PMC article.
-
A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Antiviral Res. 2008. PMID: 18571246 Review.
-
Can the generic antiretroviral industry support access to a universal antiretroviral regimen?Curr Opin HIV AIDS. 2017 Jul;12(4):390-397. doi: 10.1097/COH.0000000000000382. Curr Opin HIV AIDS. 2017. PMID: 28441147 Review.
Cited by
-
Conducting an ongoing HIV clinical trial during the COVID-19 pandemic in Uganda: a qualitative study of research team and participants' experiences and lessons learnt.BMJ Open. 2021 Apr 21;11(4):e048825. doi: 10.1136/bmjopen-2021-048825. BMJ Open. 2021. PMID: 33883157 Free PMC article.
-
Global Health Commodities Supply Chain in the Era of COVID-19 Pandemic: Challenges, Impacts, and Prospects: A Systematic Review.J Multidiscip Healthc. 2024 Apr 11;17:1523-1539. doi: 10.2147/JMDH.S448654. eCollection 2024. J Multidiscip Healthc. 2024. PMID: 38623396 Free PMC article. Review.
-
The impact of the COVID-19 pandemic on people living with HIV: a cross-sectional study in Caracas, Venezuela.BMC Infect Dis. 2024 Jan 15;24(1):87. doi: 10.1186/s12879-023-08967-6. BMC Infect Dis. 2024. PMID: 38225550 Free PMC article.
-
The dynamic interaction between COVID-19 and shipping freight rates: a quantile on quantile analysis.Eur Transp Res Rev. 2022;14(1):43. doi: 10.1186/s12544-022-00566-x. Epub 2022 Sep 16. Eur Transp Res Rev. 2022. PMID: 38625327 Free PMC article.
-
Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and antiretroviral treatment refills: A systematic review and meta-analysis.PLoS Med. 2022 Mar 22;19(3):e1003959. doi: 10.1371/journal.pmed.1003959. eCollection 2022 Mar. PLoS Med. 2022. PMID: 35316272 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources